TABLE 2.

Hepatic values during VSL#3^® treatment at baseline and after 3 months.

	Placebo				VSL#3
	Baseline		3 months		Baseline		3 months
Total number	30		30		30		30
Sex	Males	Females	Males	Females	Males	Females	Males	Females
AST (IU/l)	51.2 ± 9.1	53.9 ± 10.3	49.7 ± 8.9	52.8 ± 9.5	53.4 ± 10.1	52.7 ± 9.4	46.5 ± 8.8*^	44.4 ± 7.6*^
ALT (IU/l)	60.1 ± 15.1	56.7 ± 14.0	57.8 ± 14.4	57.2 ± 14.1	59.2 ± 15.0	58.3 ± 14.9	48.3 ± 10.1*^	52.7 ± 11.8*^
AST/ALT	0.85 ± 0.05	0.95 ± 0.08	0.86 ± 0.05	0.92 ± 0.07	0.90 ± 0.06	0.90 ± 0.06	0.96 ± 0.05*^	0.84 ± 0.04*^
γ-GT (IU/l)	36.1 ± 7.0	36.9 ± 7.7	35.4 ± 6.8	35.1 ± 6.6	35.8 ± 6.8	35.9 ± 6.9	28.2 ± 5.9*^	29.4 ± 6.0*^
HIS	33.9 ± 2.0	34.2 ± 2.2	34.9 ± 2.4	35.3 ± 2.6	35.1 ± 2.5	35.6 ± 2.7	34.1 ± 2.1*^	34.7 ± 2.3*^

Data are expressed as mean ± SDs. *p < 0.05 vs. baseline; ^p < 0.05 vs. placebo. AST, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, gamma-glutamyltransferase; HSI, hepatic steatosis index.